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Tort law has long distinguished drugs from most other prod-
ucts. For example, the privity requirement imposed by
Winterbottom v. Wright' in 1842 remained the law for most prod-
ucts2 until MacPherson v. Buick Motor Co.3 was decided in 1916.
* United States District Court Judge for the Eastern District of New York. B.A., Yale,
1950; J.D., Yale Law School, 1953.
** A.B., Princeton, 1975; J.D., Yale Law School, 1978.
152 Eng. Rep. 402 (1842). The Winterbottom plaintiff was injured when the mail-coach
he was operating broke down and he was hurled to the ground. Id. at 403. The defendant had
been hired by the Postmaster-General to maintain the mail-coaches in a "fit, proper, safe
and secure state and condition." The plaintiff alleged that his injuries were caused by the
defendant's negligence in performing the maintenance contract. Id. at 402-03. Noting that
the defendant could be held liable in negligence only if he owed the plaintiff a duty of care,
the court determined that a duty in this case could only arise out of the contract between
the defendant and the Postmaster-General. Id. at 405. Thus, the court held thatonly those
parties in privity to the contract could bring an action for its negligent performance. Id. If
such a limitation were not imposed, the court concluded, "the most absurd and outrageous
consequences . . . would ensue." Id. See generally L. FRUMER & M. FRIEDMAN, PRODUCTS
LIABILrrY § 5.01 (1978).
2 See, e.g., S.H. Kress & Co. v. Lindsey, 262 F. 331 (5th Cir. 1919); Cadillac Motor Car
Co. v. Johnson, 221 F. 801 (2d Cir. 1915); Huset v. J.I. Case Threshing Mach. Co., 120 F.
865 (8th Cir. 1903); Altorfer Bros. Co. v. Green, 236 Ala. 427, 183 So. 415 (1938); Chrystal
Coca-Cola Bottling Co. v. Cathey, 83 Ariz. 163, 317 P.2d 1094 (1957) (dictum); Pelletier v.
D4pont, 124 Me. 269, 128 A. 186 (Me. 1925); Pittman v. Gas & Elec. Co., 241 Mass. 322, 135
N.E. 223 (1922); Wood v. Sloan, 20 N.M. 127, 148 P. 507 (1915); McCaffrey v. Mossberg &
Granville Mfg. Co., 23 R.I. 381, 50 A. 651 (1901); Burkett v. Studebaker Bros. Mfg. Co., 126
Tenn. 467, 150 S.W. 421 (1912). For an interesting early discussion in which the author
concluded that the Winterbottom privity requirement was the exception rather than the rule,
see 32 HARv. L. REv. 89 (1918).
By the early twentieth century the Winterbottom privity rule had been adopted in a
majority of jurisdictions. See FRUMER & FRIEDMAN, supra note 1, at § 5.01; W. PROSSER, LAW
OF TorS § 96, at 641-42 (4th ed. 1971). Two basic reasons were given for the rule. First, the
manufacturer could not foresee or anticipate injury to those other than his immediate pur-
chaser. The weakness of this reasoning is apparent, however, when one recalls that a manu-
facturer's immediate purchaser is usually a retailer, not a consumer. The second and more
forceful reason was stated by the court in Huset v. J.I. Case Threshing Mach. Co., 120 F.
865 (8th Cir. 1903):
[A] wise and conservative public policy has impressed the courts with the view
that there must be a fixed and definite limitation to the liability of manufacturers
and vendors in the construction and sale of complicated machines and structures
which are to be operated or used by the intelligent and the ignorant, the skillful
and the incompetent, the watchful and the careless, parties that cannot be known
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Long before MacPherson, however, the New York Court of Appeals,
in Thomas v. Winchester,4 held a drug manufacturer liable to a
remote user not in privity with the defendant, recognizing that the
drug in question was an "inherently dangerous" product which
should be governed by different liability rules.
Today, tort law seems to be moving towards strict liability for
most products. 5 Yet, the landmark cases in this movement generally
to the manufacturer or vendors, and who use the articles all over the country
hundreds of miles distant from the place of their manufacture or original sale ...
Id. at 867. See generally W. PROSSER, supra, § 96.
Injuries caused by an "imminently" or "inherently" dangerous product provided the only
notable exception to the privity rule. See, e.g., Huset v. J.I. Case Threshing Mach. Co., 120
F. 865, 870 (8th Cir. 1903) (dictum); Blood Balm Co. v. Cooper, 83 Ga. 457, 10 S.E. 118 (1889);
Roberts v. Anheuser-Busch Brewing Ass'n, 211 Mass. 449, 98 N.E. 95 (1912); Thomas v.
Winchester, 6 N.Y. 397 (1852). The "inherently dangerous" rule was often applied to defective
food. See Tomlinson v. Armour & Co., 75 N.J.L. 748, 70 A. 314 (1908); Catani v. Swift &
Co., 251 Pa. 52, 95 A. 931 (1915); Mazetti v. Armour & Co., 75 Wash. 622, 135 P. 633 (1913);
note 4 infra.
3 217 N.Y. 382, 111 N.E. 1050 (1916). The plaintiff in MacPherson was injured when the
wheel of his car "crumbled into fragments." Id. at 385, 111 N.E. at 1051. Although the wheel
had not been manufactured by the defendant, its defective condition was deemed to have
been discoverable by the defendant when the car was assembled. Id. at 385, 111 N.E. at 1051.
Rejecting the privity requirement, the court reasoned that since there was "knowledge of a
danger, not merely possible, but probable," which "in the usual course of events" could "be
shared by others than the buyer," id. at 389-90, 111 N.E. at 1053, liability could properly be
imposed for a third party's injuries. Observing that "[p]recedents drawn from the days of
travel by stagecoach do not fit the conditions of travel to-day," id. at 391, 111 N.E. at 1053,
the MacPherson court concluded that liability should be imposed upon an auto manufacturer
regardless of a plaintiffs privity because a car is "reasonably certain to place life and limb
in peril when negligently made." Id. at 389, 111 N.E. at 1053.
6 N.Y. 397 (1852). Holding a drug manufacturer liable for a remote user's injuries
notwithstanding lack of privity, id. at 409-10, the Thomas court reasoned that where "an act
of negligence imminently dangerous to the lives of others" is committed, "the party guilty of
the negligence is liable to the party injured, whether there be a contract between them or
not . . . ." Id. at 410. Later cases clarified the Thomas rationale, holding that negligence
could be inferred where it was shown that the product was inherently dangerous and that
plaintiff was injured by contact with the substance. Karr v. Inecto, Inc., 247 N.Y. 360, 160
N.E. 398 (1928); Maher v. Clairol, Inc., 263 App. Div. 848, 31 N.Y.S.2d 751 (2d Dep't 1941);
Petzold v. Roux Labs., 256 App. Div. 1096, 11 N.Y.S.2d 565 (2d Dep't 1939); Bundy v. Ey-
Teb, Inc., 160 Misc. 325, 289 N.Y.S. 905 (N.Y.C. Civil Ct. Kings County 1935). But see
Sanders v. Clairol, Inc., 2 App. Div. 2d 857, 155 N.Y.S.2d 945 (2d Dep't 1956) (mem.).
Either lack of adequate warning or mislabeling could provide a basis for relief under this
theory. See Commissioners of State Ins. Fund v. City Chemical Corp., 290 N.Y. 64, 48
N.E.2d 262 (1943); Willson v. Faxon, Williams & Faxon, 208 N.Y. 108, 101 N.E. 799 (1913);
Halloran v. Parke, Davis & Co., 245 App. Div. 727, 280 N.Y.S. 58 (2d Dep't 1935) (per
curiam); Marcus v. Specific Pharm., Inc., 82 N.Y.S.2d 194 (Sup. Ct. N.Y. County 1948);
Bundy v. Ey-Teb, Inc., 160 Misc. 325, 289 N.Y.S. 905 (N.Y.C. Civil Ct. Kings County 1935).
But see Parker v. State, 201 Misc. 416, 105 N.Y.S.2d 735 (Ct. Cl. 1951) (dictum), affl'd, 280
App. Div. 157, 112 N.Y.S.2d 695 (3d Dep't 1952).
1 See Donnelly, After the Fall of the Citadel: Exploitation of the Victory or Considera-
tion of All Interests?, 19 SyancusE L. REv. 1 (1967); Gilliam, Products Liability In a Nutshell,
37 OR. L. REV. 119 (1958); Jenkins, The Product Liability of Manufacturers: An Understand-
ing And Exploration, 4 AKRON L. REV. 135 (1971); Keeton, Products Liability-Current
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have involved machines, such as cars' and manufacturing equip-
ment,7 rather than drugs. The purpose of this Article is to consider
whether the strict liability rules developed in the machinery cases
should be applied to drugs, particularly to the increasing numbers
of drugs whose defects are "unforeseeable." ' The past controversy
over thalidomide and the recent controversy over "DES", a syn-
thetic hormone given to pregnant women to prevent miscarriages
but which increases the risk of cervical and vaginal cancer in their
daughters, provide two examples of unforseeable drug defects.
Cases such as these may be among the rising number of drug liabil-
ity cases in the lower state and federal courts, at least some of which
may soon be ripe for authoritative decision by higher courts.
It may be well to begin by considering some of the significant
ways in which drugs differ from machines. First, the vast majority
of machine defects result from failures in the manufacturing process
and may properly be termed "construction defects."9 In contrast,
when drugs reach the consumer they are, generally speaking, in the
condition their manufacturer intended. Injuries resulting from their
reasonable use usually are attributable to a defect in "design,"' 0
Developments, 40 Tsx. L. REv. 193 (1961); Prosser, The Fall of the Citadel (Strict Liability
to the Consumer), 50 MINN. L. Rzv. 791 (1961); Prosser, The Assault Upon the Citadel (Strict
Liability to the Consumer), 69 YALE L.J. 1099 (1960); Rheingold, The Expanding Liability of
the Product Supplier: A Primer, 2 HOFSTRA L. REv. 521 (1974).
' E.g., Cranin v. J.B.E. Olson Corp., 8 Cal. 3d 121, 501 P.2d 1153, 104 Cal. Rptr. 433
(1972) (en banc); Elmore v. American Motors Corp., 70 Cal. 2d 578, 451 P.2d 84, 75 Cal. Rptr.
652 (1969) (en banc); Henningsen v. Bloomfield Motors, Inc., 32 N.J. 358, 161 A.2d 69
(1960); Codling v. Paglia, 32 N.Y.2d 330, 298 N.E.2d 622, 345 N.Y.S.2d 461 (1973); Bolm v.
Triumph Corp., 33 N.Y.2d 151, 305 N.E.2d 769, 350 N.Y.S.2d 644 (1973).
7 E.g., Messina v. Clark Equip. Co., 263 F.2d 291 (2d Cir.), cert. denied, 359 U.S. 1013
(1959); Fleming v. John Deere Plow Co., 158 F. Supp. 399 (W.D. Pa. 1958); Greenman v.
Yuba Prods., Inc., 59 Cal. 2d 57, 377 P.2d 897, 27 Cal. Rptr. 697 (1962) (en banc); Winnet v.
Winnet, 57 Ill. 2d 7, 310 N.E.2d 1 (1974); Krahn v. J.L. Owens Co., 125 Minn. 33, 145 N.W.
626 (1914); Micallef v. Miehle Co., 39 N.Y.2d 376, 348 N.E.2d 571, 384 N.Y.S.2d 115 (1976).
1 For purposes of this Article, "unforeseeable" defects are those which cannot be discov-
ered by use of "due care." All defects may be discoverable given infinite time, money and
talent to conduct research, but the limited resources actually available to even the largest
manufacturers make many defects, in practice, "unforeseeable" when they are marketed.
I "Construction defect" implies that the product which entered the market place was a
departure from the intended design. As Professor Wade has noted, in the context of products
liability, it is the construction defect, the flaw in the metal, the cracked soft drink bottle,
which is most often associated with strict liability in tort. Wade, On the Nature of Strict Tort
Liability for Products, 44 Miss. L.J. 825, 829-30, 833 (1973). The strict-liability doctrine
assumes that product-construction defects usually result from fault which exists but may
be difficult to prove. Keeton, Products Liability and the Meaning of Defect, 5 ST. MARY's
L.J. 30, 34 (1973); Wade, supra, 825-26.
10 Generally, "design defect" refers to a finished product that conforms to a plan which
for some reason proves to be flawed. In contrast to construction defects, design defects are
not easily defined. The California courts' interpretation of the term, for example, varied
before a dual theory of strict products liability was formulated in Barker v. Lull Engineering
19791
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rather than in "construction." This distinction in the nature of de-
fects is critical in the area of strict products liability.
Second, the principles by which machines work are fairly well
understood; close inspection of the design and relatively brief test-
ing will reveal a machine's latent defects. The principles by which
drugs work are less well understood, since drugs affect the complex
mechanisms of the body in myriad ways, and the same drug may
produce different effects in different individuals. Scrutiny of a
drug's design and careful, expensive, time-consuming testing can-
not insure discovery of all its latent hazards." Injuries from drug
hazards may, in practice, be unforeseeable, the result of scientific
limitations rather than negligence in design or construction. Al-
though machines often can be redesigned to eliminate defects with-
out impairing their operation, redesign of a drug may be impossible.
Side effects are frequently inseparable from the product itself and
the current level of scientific knowledge about drug effects may not
permit tailoring a drug to specific needs or conditions, much less to
Co., 20 Cal. 3d 413, 573 P.2d 443, 143 Cal. Rptr. 225 (1978). See, e.g., Buccery v. General
Motors Corp., 60 Cal. App. 3d 533, 132 Cal. Rptr. 605 (1976) (product with design which
causes injury when used or misused in a foreseeable manner is defective if available technol-
ogy could avoid the danger at a reasonable cost); Baker v. Chrysler Corp., 55 Cal. App. 3d
710, 127 Cal. Rptr. 745 (1976) (determination of a defective design must include a considera-
tion of the economic and technological feasibility of alternatives); Hyman v. Gordon, 35 Cal.
App. 3d 769, 111 Cal. Rptr. 262 (1973) (overall design may be defective if a necessary article
functions without injury in one area yet is the proximate cause of harm in another). For a
discussion of the Barker test, see text accompanying notes 43-46 infra.
" Under the Food and Drug Act, 21 U.S.C. § 355(a) (1976):
No person shall introduce or deliver for introduction into interstate commerce
any new drug, unless an approval of an application filed pursuant to subsection (b)
of this section is effective with respect to such drug.
Before an application can be filed, however, extensive laboratory research and testing must
be performed. Animals are the most common subjects in this step of the testing process, but
since the drugs are intended for human use, this testing is not optimal. See Hubbard,
Preclinicol Problems of New Drug Development, in REGULATING NEW DRUGS 35, 41-42 (R.L.
Landau ed. 1973).
A new drug application made to the Federal Food and Drug Administration (FDA), is
approved only after the FDA is convinced that the laboratory experiments support clinical
trials. In the first clinical test, the drug is administered to a small group of patients who are
observed to determine the rate and degree of absorption, metabolization and elimination of
the drug as well as the tolerated dosage and obvious toxicity. The next step tests the drug's
ability to prevent or counteract symptoms. In step three the drug is distributed to a larger
patient population, often through out-patient services. Its purpose is to tailor development
of the proper dosage. For a complete discussion of the premarketing testing procedure at the
clinical level, see Gold & Azarnoff, New Drug Investigations in Man: Continuing Unresolved
Problems, in REGULATING NEW DRUGs 62, 62-67 (R.L. Landau ed. 1973). As a result of the
testing procedures, "[tihe maximum number of patients (3,000) likely to get a drug in Phase
I testing, the last step before FDA approval, will give investigators a 95 percent chance of
finding an adverse reaction that might occur once in 1,000 patients." W. Ross, THE
LiFFDEATH RATIO 207-08 (1977).
[Vol. 53:517
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specific individuals. One who seeks a particular therapeutic effect
often faces a difficult choice: either accept the drug's defects or
forego its benefits. 12
Finally, while the hazards of machine defects seldom depend
upon the particular operator or user, a drug's hazards may vary with
the consumer's age, genetic makeup, body chemistry, eating habits
and state of health. Proper dosage also may vary between consum-
ers, and foods eaten or other drugs consumed may affect a drug's
therapeutic action as well as its side effects. In short, there is an
infinite variety of drug reactions, and a proportionately large num-
ber of potential liability claims.
These distinctive aspects of drugs suggest at the outset that
modem liability rules, which have developed primarily in the con-
text of defective machinery cases, may be inadequate tools for ap-
portioning losses which result from drug injuries, particularly those
that were unforeseeable at the time of manufacture and sale. Al-
though the early drug cases which sounded in negligence at first
glance appear to be applicable, they focussed on adequacy of warn-
ing 3 and, therefore, bear little on the problem of unforeseeable drug
11 In making his decision, the user's own knowledge and observations leave him uniquely
defenseless against a drug's latent defects. Adequate warning of risks and possible side effects
is essential to permit safe use.of a drug. See note 13 infra; Gardner, Increasing Patient
Awareness in Drug Therapy: Ramifications of a Patient Package Insert Requirement, 66 GEO.
L.J. 837 (1978).
3 Drug manufacturers' liability traditionally has been linked to adequacy of warning.
What constitutes "adequate" in a particular circumstance is, of course, subject to dispute.
Generally, a warning must be designed with respect to medium and urgency so that its
message will be conveyed to the user. Jackson v. Coast Paint & Lacquer Co., 499 F.2d 809,
814 (9th Cir. 1974); Canifax v. Hercules Powder Co., 237 Cal. App. 2d 44, 46 Cal. Rptr. 552
(1965). A prescription drug's warning, however, need not be calculated to reach the ultimate
user. Rather, its warning is adequate if the manufacturer has made reasonable efforts to warn
the patient's physician, who will act as a "learned intermediary" in communicating the
information. See Sterling Drug, Inc. v. Yarrow, 408 F.2d 978, 993 (8th Cir. 1969); Sterling
Drug, Inc. v. Cornish, 370 F.2d 82, 85 (8th Cir. 1966); Stottlemire v. Cawood, 213 F. Supp.
897, 899 (D.D.C. 1963); Love v. Wolf, 226 Cal. App. 2d 378, 38 Cal. Rptr. 183 (1964).
Adequacy of warning is determined by negligence standards; i.e., the manufacturer must
employ reasonable efforts to inform the user of potential dangers. See generally Parke-Davis
& Co. v. Stromsodt, 411 F.2d 1390 (8th Cir. 1969); Carmen v. Eli Lilly & Co., 109 Ind. App.
76, 32 N.E.2d 729 (1941) (en banc); Rumsey v. Freeway Manor Minimax, 423 S.W.2d 387
(Tex. Ct. of Civ. App. 1968). Although actual warning is not required, the manufacturer must,
in order to avoid liability, provide the warning in a manner which is reasonably designed to
attract the user's attention. Hubbard-Hall Chem. Co. v. Silverman, 340 F.2d 402, 405 (1st
Cir. 1965). Liability will not be imposed, however, if the user had actual notice of the danger,
even if the warning as provided was inadequate. Nelson v. Brunswick Corp., 503 F.2d 376,
379 (9th Cir. 1974).
Content, of course, is the most critical part of the warning. Since, however, the tradi-
tional duty to warn extends only to those hazards of which the manufacturer could or should
19791
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hazards that cannot be warned against.
This Article begins with a close look at the development of New
York's common law of strict products liability. The succeeding sec-
tions leave the New York cases to consider solutions proposed by
other jurisdictions and authorities. The Article concludes with a
short discussion of more radical alternatives to drug liability prob-
lems which may resist the traditional solutions.
MANUFACTURER'S LIABILrTY IN NEw YORK
Any discussion of the law of strict product liability in New York
must begin with the court of appeals' landmark decision in Codling
v. Paglia.4 The case arose out of an accident caused by a defect in
the power steering system of a car manufactured by Chrysler Corp."5
The injured driver and passenger of the second car involved in the
accident brought suit against the manufacturer of the first car,
claiming negligence and breach of warranty. 6 Focussing on the war-
ranty claim, the court of appeals addressed the question whether
New York would continue to recognize privity as an essential ele-
ment of a warranty cause of action.17 Noting the many exceptions
to the privity requirement that had been created to avoid injustices
and the strong policy considerations weighing against continued
adherence to the doctrine, 8 the court concluded that the time had
have been aware at the time of manufacture, Bichler v. Willing, 58 App. Div. 2d 331, 335,
397 N.Y.S.2d 57, 59 (1st Dep't 1977); Donigi v. American Cyanamid Co., 57 App. Div. 2d
760, 394 N.Y.S.2d 422, 423 (1st Dep't 1977), aff'd, 43 N.Y.2d 935, 374 N.E.2d 1245, 403
N.Y.S.2d 894 (1978) (mem.); cf. Parker v. State, 201 Misc. 416, 105 N.Y.S.2d 735, 741 (Ct.
Cl. 1951), affd, 280 App. Div. 157, 112 N.Y.S.2d 695 (3d Dep't 1952) (manufacturer has no
duty to provide warning of risks generally known), it seems clear that drug manufacturers'
liability for unforeseeable hazards can in no way be predicated upon a breach of this duty.
1 32 N.Y.2d 330, 298 N.E.2d 622, 345 N.Y.S.2d 461 (1973).
11 Id. at 337, 298 N.E.2d at 625, 345 N.Y.S.2d at 465. The Codling plaintiff was injured
when the Paglia's automobile suddenly swerved to the left, crossed the middle of the road,
and collided with the car in which the plaintiff was a passenger. Id. at 335, 298 N.E.2d at
624, 345 N.Y.S.2d at 463. The plaintiff sued Paglia for negligence and Chrysler for negligence
and breach of warranty. Paglia cross-claimed against Chrysler to recover any damages
awarded Codling against him. Id. at 335, 248 N.E.2d at 624, 345 N.Y.S.2d at 463-64. The jury
found Chrysler liable for breach of warranty, and both the defendants and the plaintiff
recovered judgments against Chrysler. Id. at 336-37, 298 N.E.2d at 625, 345 N.Y.S.2d at 464.
Id. at 335, 298 N.E.2d at 624, 345 N.Y.S.2d at 463.
'7 See id. at 338, 298 N.E.2d at 625-26, 345 N.Y.S.2d at 465-66.
As a justification for expanding manufacturers' liability for injuries caused by defec-
tive products, the court stated:
Today as never before the product in the hands of the consumer is often a most
sophisticated and even mysterious article. Not only does it usually emerge as a
sealed unit with an alluring exterior rather than as a visible assembly of component
parts, but its functional validity and usefulness often depend on the application of
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come to "lay down a broad principle, eschewing the temptation to
devise more proliferating exceptions."" Accordingly, the court artic-
ulated a theory of strict products liability, under which the absence
of privity would not bar recovery:
[T]he manufacturer of a defective product is liable to any person
injured or damaged if the defect was a substantial factor in bring-
ing about his injuries or damages; provided: (1) that at the time
of the occurence the product is being used (whether by the person
injured or damaged or by a third person) for the purpose and in
the manner normally intended, (2) that if the person injured or
damaged is himself the user of the product he would not by the
exercise of reasonable care have both discovered the defect and
perceived its danger, and (3) that by the exercise of reasonable care
the person injured or damaged would not otherwise have averted
his injury or damages. 2
Although the Codling court did not specify under what circum-
stances this newly adopted theory would apply, it seemed equally
applicable to design and construction defects.2 1 This issue appar-
ently was resolved some six months later in Bolm v. Triumph
Corp.,2 where the court of appeals was again presented with the
issue of manufacturer's liability for injuries attributable to a prod-
uct defect. In contrast to the defective automobile steering mecha-
nism in Codling, apparently the result of faulty construction, the
subject of the Bolm action was a motorcycle parcel grid, located and
designed in such a manner that it aggravated the plaintiff's injuries
during a collision with another vehicle. 2 Predicating its decision on
"general negligence principles,"u the Bolm court concluded:
electronic, chemical or hydraulic principles far beyond the ken of the average con-
sumer .... In today's world it is often only the manufacturer who can fairly be
said to know and to understand when an article is... safely made for its intended
purpose.
Id. at 340, 298 N.E.2d at 627, 345 N.Y.S.2d at 468.
11 Id. at 339, 298 N.E.2d at 626, 345 N.Y.S.2d at 467.
Id. at 342, 298 N.E.2d at 628-29, 345 N.Y.S.2d at 469-70.
21 The court's opinion was most notable as an expansion of strict products liability to
include innocent bystanders. The question whether the test developed in Codling would be
applied to design defects, however, was not before the court.
33 N.Y.2d 151, 305 N.E.2d 769, 350 N.Y.S.2d 644 (1973).
2 Id. at 153-54, 305 N.E.2d at 770, 350 N.Y.S.2d at 645-46. David Bolhn incurred aggra-
vated pelvic and genital injuries in the course of a collision between his motorcycle and an
automobile when he came into contact with a metal luggage rack, or parcel grid, which
extended approximately three inches above the saddle and was located on top of the motorcy-
cle's gas tank. Id. at 153-54, 305 N.E.2d at 770, 350 N.Y.S.2d at 646.
21 Id. at 158, 305 N.E.2d at 772-73, 350 N.Y.S.2d at 649.
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We perceive of no sound reason, either in logic or experience...
why the manufacturer should not be held to a reasonable duty of
care in the design of its vehicle consonant with the state of the art
to minimize the effects of accidents. The manufacturers are not
insurers but should be held to a standard of reasonable care in
design to provide a reasonably safe vehicle in which to travel. 2
The Bolm plaintiff had alleged causes of action both in negli-
gence and strict products liability. Although it is not clear from the
opinion which claim the court was referring to,2" subsequent author-
u Id. at 158, 305 N.E.2d at 773, 350 N.Y.S.2d at 650 (quoting Larsen v. General Motors
Corp., 391 F.2d 495, 502-03 (8th Cir. 1968)) (emphasis added). Bolm is more often cited for
its discussion of two other significant issues in the area of products liability. First, it reaf-
firmed the latent-patent distinction adopted 25 years earlier in Campo v. Scofield, 301 N.Y.
468, 471, 95 N.E.2d 802, 804 (1950). In Campo, the New York Court of Appeals had estab-
lished the rule that if the plaintiff's injuries were the result of a patent defect recovery should
be denied:
If a manufacturer does everthing necessary to make the machine function
properly for the purpose for which it is designed, if the machine is without any
latent defect, and if its functioning creates no danger or peril that is not known to
the user, then the manufacturer has satisfied the law's demands . .. . [T]he
manufacturer is under no duty to render a machine or other article 'more' safe-as
long as the danger to be avoided is obvious and patent to all.
Id. at 472, 95 N.E.2d at 804.
The latent-patent distinction, which had been the subject of much criticism, see Merced
v. Auto Pak Co., 533 F.2d 69, 76 n.8 (2d Cir. 1976); Pike v. Hough Co., 2 Cal. 3d 465, 474,
467 P.2d 229, 235, 85 Cal. Rptr. 629, 635 (1970); Bynnes v. Economic Mach. Co., 41 Mich.
App. 192, 202, 200 N.W.2d 104 (1972); Palmer v. Massey-Ferguson, Inc., 3 Wash. App. 508,
512, 476 P.2d 713, 718 (1970); 2 F. HARPER & F. JAMES, THE LAW OF ToRTs § 28.5 (1956);
Donaher, The Technological Expert in Products Liability Litigation, 52 TEx. L. REV. 1303,
1304 (1974); Marschall, An Obvious Wrong Does Not Make a Right: Manufacturers'Liability
for Patently Dangerous Products, 48 N.Y.U.L. REV. 1065, 1081 (1973); Rheingold, The Ex-
panding Liability of the Product Supplier: A Primer, 2 HoFSTRA L. RPv. 521, 541 (1974);
Twerski, From Codling, to Bolm, to Velez: "Triptych of Confusion," 2 HOFsTA L. REv. 489,
498-99 (1974), was finally discarded by the court of appeals in 1976. Micallef v. Miehle Co.,
39 N.Y.2d 376, 387, 348 N.E.2d 571, 578, 384 N.Y.S.2d 115, 122 (1976).
Bolm is also noted for its rejection of the so-called "second-collision" rule, under which
manufacturers were absolved of liability when the defect merely contributed to the plaintiff's
injuries but did not cause the accident. 33 N.Y.2d at 157, 305 N.E.2d at 772, 350 N.Y.S.2d
at 649; see Edgar v. Nachman, 37 App. Div. 2d 86, 323 N.Y.S.2d 53 (3d Dep't 1971); Brown,
Products Liability: The Genesis of "Second Collision," N.Y.S.B.J. 21 (1979).
28 Another design case, Micallef v. Miehle Co., 39 N.Y.2d 376, 348 N.E.2d 571, 384
N.Y.S.2d 115 (1976), presents similar problems of interpretation. In Micallef, the plaintiff's
hand was injured when he attempted to remove an imperfection from the plate of a printing
machine he was operating. Id. at 379-80, 348 N.E.2d at 573, 384 N.Y.S.2d at 117. Discussing
the scope of manufacturers' liability for design defects, the court enumerated several factors
which should be considered by the trial court, such as matters of "'cost, function, and
competition as narrowing the design choices,'" id. at 386, 348 N.E.2d at 578, 384 N.Y.S.2d
at 121 (quoting Rheingold, Expanding Liability of the Product Supplier: A Primer, 2 HoFsTRA
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ity views BoIm as establishing a rule to be applied in strict products
litigation.27 More importantly, the case seems to govern where the
injury-producing product is manufactured as intended and the al-
leged "defect" is inherent in its design. While Codling has never
been expressly narrowed to instances of construction defects, such
a limitation seems implicit in the Bolm opinion. Thus, without
express acknowledgement, the New York decisions indicate that the
essence of design defect liability is negligence, while strict liability
will apply where "something has gone wrong"" in the manufactur-
ing process.
If the test is to be negligence, a drug manufacturer invariably
will be absolved from liability for injuries caused by unforeseeable
defects in its products. Perhaps this is the proper result, but it
should be noted that the New York cases have not yet considered
the unique policy questions raised by drugs which are created and
marketed with due care and yet, after years pass, turn out to be
defective in design.2' Accordingly, the following sections of this
Article consider different approaches by other jurisdictions and
authorities to the defective design problem.
L. REv. 521, 537 (1974)), and "whether [the manufacturer] kept abreast of recent scientific
developments. . . and the extent to which any tests were conducted to ascertain the dangers
of the product." 39 N.Y.2d at 386,348 N.E.2d at 578,384 N.Y.S.2d at 121 (citations omitted).
Just as in Bolm, it is unclear from the opinion which cause of action the court was referring
to when it discussed these factors. It appears, however, that Micallef is susceptible of the
same interpretation which has followed the court's earlier decision in Bolm. See note 27 and
accompanying text infra.
" See Cousins v. Instruments Flyers, Inc., 58 App. Div. 2d 336, 396 N.Y.S.2d 655 (1st
Dep't 1977), aff'd per curiam, 44 N.Y.2d 698, 376 N.E.2d 914, 405 N.Y.S.2d 441 (1978);
Weinberger, Design Defect Litigation in New York: What is the Standard?, 30 BROOKLYN
BARuLsTR 11 (1978); NEw YORK PAWERN JURY INSTRUCTONs 2:141 (Supp. 1977).
2 Wade, supra note 9, at 831.
" The plight of the helpless user in New York may have been increased by a recent
decision of the New York Court of Appeals, Thornton v. Roosevelt Hospital, No. 135 (Ct. App.
May 10, 1979), which held that a strict liability cause of action was time-barred where a
cancer-causing drug had been injected 20 years before the cancer was discovered and suit
filed. Reaffirming the vitality of Victorson v. Bock Laundry Machine Co., 37 N.Y.2d 395, 373
N.Y.S.2d 39, 335 N.E.2d 275 (1975), the court of appeals in Thornton held that the product
liability cause of action "accrued at the time of invasion of decedent's body, and not at the
time the decedent's cancerous condition became apparent." Thornton v. Roosevelt Hospital,
No. 135, slip op. at 1 (Ct. App. May 10, 1979). Under this decision, unforeseeable defects
which surface more than 3 years after ingestion of a drug would be beyond the reach of strict
product liability in New York. A large percentage of potential drug claims promise to be
affected by this decision, and Judge Fuchsberg, the lone dissenter, may be correct in suggest-
ing that there is need "for rescue from an unconscionable decisional law." Id. at 5.
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OTHER APPROACHES TO DESIGN DEFECT CASES
The California Approach
Justice Traynor's landmark decision in Greenman v. Yuba
Power Products, IncY° began the development of a strict products
liability theory spanning fifteen years in the California courts. The
Greenman court announced a broad theory of strict liability: a
"defect that causes injury to a human being" would be actionable
without proof of the manufacturer's negligence.' Justice Traynor
later observed that the meaning of "defect" could vary according to
the factual setting, and therefore suggested that the legal definition
of the term should be developed through precedent.32 The Greenman
theory was considered by manys to be equivalent to that set forth
in the Restatement (Second) of Torts § 402A, which would impose
10 59 Cal. 2d 57, 377 P.2d 897, 27 Cal. Rptr. 697 (1962). In Greenman, the plaintiff was
seriously injured while operating a lathe when the piece of wood he was working on flew out
of the machine and struck him in the head. Id. at 58, 377 P.2d at 898, 27 Cal. Rptr. at 698.
Ten months later he sued the manufacturer and the retailer for breach of express and implied
warranties and negligence. Id. The trial court ruled that there was no evidence that the
retailer was negligent or had breached any implied or expressed warranties. Id. at 59, 377 P.2d
at 898-99, 27 Cal. Rptr. at 698-99. Without specifying the grounds, however, the jury found
the manufacturer liable and awarded the plaintiff $65,000. Id. at 59, 377 P. 2d at 899, 27 Cal.
Rptr. at 699. On appeal, the defendant claimed that the warranty cause of action was barred
because the plaintiff failed to give timely notice of the breach. Justice Traynor, writing for
the California Supreme Court, concluded that the warranty action was not barred, id. at 61,
377 P.2d at 900, 27 Cal. Rptr. at 700, and then proceeded to outline the requirements for a
strict products liability claim in California. Id. at 61, 377 P.2d at 901, 27 Cal. Rptr. at 701;
see note 31 and accompanying text infra.
11 59 Cal. at 61, 377 P.2d at 900, 27 Cal. Rptr. at 700. The Greenman court rejected the
theory that strict products liability is predicated upon a breach of an express or implied
warranty, id., and thus departed from the then prevailing view in the majority of jurisdic-
tions. See id., and cases cited therein.
32 Traynor, The Ways and Meanings of Defective Products and Strict Liability, 32
TaEN. L. Rav. 363, 371 (1965).
3 E.g., Schenfeld v. Norton Co., 391 F.2d 420 (10th Cir. 1968); Butaud v. Suburban
Marine & Sporting Goods, Inc., 555 P.2d 42 (Alas. 1976); Matter v. Coca-Cola Bottling Co.,
311 So.2d 417 (Fla. App. 1974); Suvada v. White Motor Co., 32 Ill. 2d 612, 210 N.E.2d 182
(1965); Hawkeye-Security Ins. Co. v. Ford Motor Co., 174 N.W.2d 672 (Iowa 1970); Brooks
v. Dietz, 218 Kan. 698, 545 P.2d 1104 (1976); McCormack v. Hankscraft Co., 278 Minn. 322,
154 N.W.2d 488 (1967); State Stove Mfg. Co. v. Hodges, 189 So. 2d 113 (Miss. 1966), cert.
denied, 386 U.S. 912 (1967); Johnson v. American Motors Corp., 225 N.W.2d 57 (N.D. 1974);
Temple v. Wean United, Inc., 50 Ohio St. 2d 317, 364 N.E.2d 267 (1977); Kirkland v. General
Motors Corp., 521 P.2d 1353 (Okla. 1974); Romano v. Westinghouse Elec. Co., 114 R.I. 451,
336 A.2d 555 (1975); Seattle First National Bank v. Tabert, 86 Wash. 2d 145, 542 P.2d 774
(1975); Dippel v. Sciano, 37 Wis. 2d 443, 155 N.W.2d 55 (1967); see Garthwait v. Burgio, 153
Conn. 290, 216 A.2d 189 (1965); Stewart v. Budget Rent-A-Car Corp., 52 Haw. 71, 470 P.2d
240 (1970); Perfection Paint & Color Co. v. Konduris, 147 Ind. App. 106, 258 N.E.2d 681
(1970); Dealers Transp. Co. v. Battery Distrib. Co., 402 S.W.2d 441 (Ky. 1966); Buttrick v.
Arthur Lessard & Sons Inc., 260 A.2d 111 (N.H. 1969).
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liability when a product is "in a defective condition unreasonably
dangerous to the user or consumer or to his property." Under this
approach, "defective" includes within its definition some "un-
reasonable danger" to the safety of the product's user, a definition
subsequently adopted in numerous jurisdictions. 5 In Cronin v.
J.B.E. Olson Corp.,36 however, the California Supreme Court noted
that the Restatement (Second) approach could burden "the injured
plaintiff with proof of an element which rings of negligence, ,37 and
concluded that such a burden would represent "a step backward"
in the development of a strict tort liability theory.1s Accordingly, the
court rejected the "unreasonably dangerous" qualification of the
Restatement (Second) and held that a showing of defectiveness
' RESTATEMENT (SECOND) OF ToRS § 402A (1965). Section 402A states:
(1) One who sells any product in a defective condition unreasonably dangerous to
the user or consumer or to his property is subject to liability for physical harm
thereby caused to the ultimate user or consumer, or to his property, if
(a) the seller is engaged in the business of selling such a product, and
(b) it is expected and does reach the user or consumer without substan-
tial change in the condition in which it is sold.
(2) The rule stated in subsection (1) applies although
(a) the seller has exercised all possible care in the preparation and sale
of his product, and
(b) the user or consumer has not bought the product from or entered
into any contractual relationship with the seller.
Id.
See, e.g., Byrns v. Riddell, Inc., 113 Ariz. 264, 550 P.2d 1065 (1976); Mattes v. Coca-
Cola Bottling Co., 311 So. 2d 417 (Fla. App. 1974); Farmer v. International Harvester Co.,
97 Idaho 742, 553 P.2d 1306 (1976); Perfection Paint & Color Co. v. Konduris, 147 Ind. App.
106, 258 N.E.2d 681 (1970); Hawkeye-Security Ins. Co. v. Ford Motor Co., 174 N.W.2d 672
(Iowa 1970); Brooks v. Dietz, 218 Kan. 698, 545 P.2d 1104 (1976); Stenberg v. Beatrice Foods
Co., 576 P.2d 725 (Mont. 1978); Buttrick v. Arthur Lessard & Sons, Inc., 110 N.H. 36, 260
A.2d 111 (1969); Cavan v. General Motors Corp., 280 Ore. 455, 571 P.2d 1249 (1977); Webb
v. Zern, 422 Pa. 424, 220 A.2d 853 (1966); Ritter v. Narragansett Elec. Co., 109 R.I. 176, 283
A.2d 255 (1971); Zaleski v. Joyce, 133 Vt. 150, 333 A.2d 110 (1975); Lamon v. McDonnell
Douglas Corp., 19 Wash. App. 515, 576 P.2d 426 (1978); Vincer v. Esther Williams All-
Aluminum Swimming Pool Co., 69 Wis. 2d 326, 230 N.W.2d 794 (1975).
11 8 Cal. 3d 121, 501 P.2d 1153, 104 Cal. Rptr. 433 (1972). Cronin was injured in an
accident which occurred while he was driving a bread delivery truck. Id. at 124, 501 P.2d at
1155, 104 Cal. Rptr. at 435. His injuries were compounded when the bread trays, installed
by the defendant and released by a defective latch, struck him and pushed him through the
truck's windshield. Id. at 124, 501 P.2d at 1155, 104 Cal. Rptr. at 435. The trial court held
for the plaintiff, id. at 124-25, 501 P.2d at 1156, 104 Cal. Rptr. at 436, and the defendant
appealed, contending, inter alia, that the trial judge erroneously had refused to instruct the
jury that the defect must be "unreasonably dangerous." Id. at 127-28, 501 P.2d at 1158, 104
Cal. Rptr. at 438. The California Supreme Court concluded that it was not necessary for the
plaintiff to prove that the defect was unreasonably dangerous. See text accompanying note
39 infra.
8 Cal. 3d at 132, 501 P.2d at 1162, 104 Cal. Rptr. at 442.
Id. at 133, 501 P.2d at 1162, 104 Cal. Rptr. at 442.
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alone would satisfy a plaintiff's strict liability burden of proof. 9
Discussing the application of this revised liability formula to design
cases, the court stated that since a "defect may emerge from the
mind of the designer as well as from the hand of the workman, ' '
no distinction could be made between construction and design de-
fects. 1
Six years later, in Barker v. Lull Engineering Co.,4" the Califor-
nia Supreme Court, noting that misinterpretations of Cronin had
flourished in the lower courts, set forth a two-part test for determin-
ing the defectiveness of a design:
[A] product is defective in design either (1) if the product has
failed to perform safely as an ordinary consumer would expect
when used in an intended or reasonably foreseeable manner, or (2)
if. . .the benefits of the challenged design do not outweigh the
risk of danger inherent in such design. 3
Among the factors to be considered under the second part of the test
are the gravity of the danger posed, the likelihood of it occurring,
the feasibility and cost of an alternative design, and the adverse
11 Id. Cronin's exclusion of "unreasonably dangerous" from the definition of "defective"
led to considerable confusion in California's lower courts. See, e.g., Buccery v. General Motors
Corp., 60 Cal. App. 3d 533, 132 Cal. Rptr. 605 (1976); Baker v. Chrysler Corp., 55 Cal. App.
3d 710, 127 Cal. Rptr. 745 (1976); Self v. General Motors Corp., 42 Cal. App. 3d 1, 116 Cal.
Rptr. 575 (1974); Hyman v. Gordon, 35 Cal. App. 3d 769, 111 Cal. Rptr. 262 (1973). This
confusion was attributed to the court's failure to propose an alternative definition. See
Hoenig, Product Design and Strict Tort Liability: Is There a Better Approach? 8 Sw. U.L.
Rrv. 109 (1976); Keeton, Product Liability and the Meaning of Defect, 5 ST. MARy's L.J. 30,
30 (1973); Keeton, Manufacturer's Liability: The Meaning of "Defect" in the Manufacture
and Design of Products, 20 SYRACUSE L. Rrv. 559 (1969); Traynor, The Ways and Meanings
of Defective Products and Strict Liability, 32 TENN. L. REv. 363 (1965); Wade, On the Nature
of Strict Tort Liability for Products, 44 Miss. L. J. 825 (1973); Wade, Strict Tort Liability
of Manufacturers, 19 Sw. L.J. 5 (1965).
40 8 Cal. 3d at 134, 501 P.2d at 1162, 104 Cal. Rptr. at 442.
41 Id. at 134, 501 P.2d at 1163, 104 Cal. Rptr. at 443.
42 20 Cal. 3d 413, 573 P.2d 443, 143 Cal. Rptr. 225 (1978). Barker was injured while
operating a forklift manufactured by the defendant, when the lift's load fell off the forks and
hit Barker as he attempted to escape injury. Id. at 419, 573 P.2d at 447, 143 Cal. Rptr. at
229. The plaintiff alleged that his injuries were caused by design defects in the forklift which
caused the machine to be unstable. Id. at 417, 573 P.2d at 445-46, 143 Cal. Rptr. at 227-28.
The jury was instructed that strict liability is "based on a finding that the product was
unreasonably dangerous for its intended use," id. at 417, 573 P.2d at 446, 143 Cal. Rptr. at
228 (emphasis added), and held for the defendant. Id. at 422, 573 P.2d at 446, 143 Cal. Rptr.
at 231. On appeal, the California Supreme Court reversed, holding that the trial court's
instructions to the jury were erroneous because they required the jury to find the defect to
be unreasonably dangerous in light of the manufacturer's concept of intended use, rather than
"defective" in light of a "reasonable use" as its prior decision in Cronin required. Id. at 435-
36, 573 P.2d at 458, 143 Cal. Rptr. at 240.
41 Id. at 418, 573 P.2d at 446, 143 Cal. Rptr. at 228 (emphasis added).
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consequences that might result from an alternative design." At-
tempting to conform the design defect action to the strict liability
formula generally, the Barker court stressed that the emphasis
would be on the product itself, rather than the conduct of the manu-
facturer. 5 The court concluded that "once the plaintiff makes a
prima facie showing that the injury was proximately caused by the
product's design, the burden should appropriately shift to the defen-
dant to prove, in light of the relevant factors, that the product is
not defective." 6
Despite its professed adherence to a strict liability scheme, the
California Supreme Court has not eliminated negligence from de-
sign defect actions by vesting the plaintiff with a set of "rebuttable
presumptions" as a part of his prima facie case." By requiring the
manufacturer to go forward with evidence of the relevant factors in
its favor, the Barker court implicitly acknowledged the negligence
character of a design defect action. While the court also stated that
the balancing of relevant factors would not require a jury determina-
tion that the defendant was negligent before liability could be im-
posed, 8 it seems clear that the manufacturer must, in effect, dis-
prove negligence.4 Thus, despite appearances, the California courts
take an approach similar to that utilized by the New York courts
" Id. at 431, 573 P.2d at 455, 143 Cal. Rptr. at 237 (citing Horn v. General Motors Corp.,
17 Cal. 3d 359, 551 P.2d 398, 131 Cal. Rptr. 78 (1976)); Henderson v. Haxnishchfeger Corp.,
12 Cal. 3d 663, 527 P.2d 353, 117 Cal. Rptr. 1 (1974); Luque v. McLean, 8 Cal. 3d 136, 501
P.2d 1163, 104 Cal. Rptr. 443 (1972); Heap v. General Motors Corp., 66 Cal. App. 3d 824,
136 Cal. Rptr. 304 (1977); Buccery v. General Motors Corp., 60 Cal. App. 3d 533, 132 Cal.
Rptr. 605 (1976); Baker v. Chrysler Corp., 55 Cal. App. 3d 710, 127 Cal. Rptr. 745 (1976);
Self v. General Motors Corp., 42 Cal. App. 3d 1, 116 Cal. Rptr. 575 (1974); Garcia v. Halsett,
3 Cal. App. 3d 319, 82 Cal. Rptr. 420 (1970)).
20 Cal. 3d at 432, 573 P.2d at 456, 143 Cal. Rptr. at 238.
" Id. at 431, 573 P.2d at 455, 143 Cal. Rptr. at 237.
,7 Under the Barker test, see text accompanying notes 43-46 supra, the defendant must
prove that, in light of the relevant factors, liability should not be imposed. Should the
defendant fail to meet this burden, the Barker test presumes the factors are in the plaintiff's
favor and enables him to prevail. Barker v. Lull Engineering, 20 Cal. 3d 413, 573 P.2d 443,
143 Cal. Rptr. 225 (1978).
"Id. at 434, 573 P.2d at 457, 143 Cal. Rptr. at 239.
" "Likelihood" of injury implies foreseeability, "gravity of danger posed" conjures a
standard of reasonableness in marketing, and "feasibility" of a different design implicates
"state of the art" technology. Thus, the burden of proving these relevant factors, while at
one time the plaintiff's, is now upon the defendant-manufacturer.
According to Dean Prosser, a plaintiff's burden of proof when seeking recovery against a
manufacturer for injuries resulting from an "unsafe product" should be similar whether he
is pursuing a negligence, warranty or strict liability theory. In any of these situations, the
plaintiff must establish that the product was the proximate cause of the injury, the injury
resulted from the product's defective condition and that the defect was present when the
product left the manufacturer. W. PROSSER, LAw OF ToaRS § 103 (4th ed. 1971).
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and, therefore, generally would not impose liability on drug manu-
facturers for unforeseeable injuries.
Restatement (Second) of Torts § 402A
Entitled "Strict Liability," section 402A of the Restatement
(Second) of Torts recommends that liability be imposed on the
seller of a product which causes injury and is "in a defective condi-
tion unreasonably dangerous to the user or consumer."50 This rule
would apply even where "the seller has exercised all possible care
in the preparation and sale of his product."'" With specific reference
to drugs, Comment h states that where a manufacturer "has reason
to anticipate that danger may result from a particular use," such a
product is defective if not accompanied by a warning.2 Similarly,
Comment i states that the seller may assume that a warning will
be read and heeded, and that "a product bearing such a warning,
which is safe for use if it is followed, is not in defective condition
nor is it unreasonably dangerous." Both the New York and Califor-
nia courts have rejected the standard set forth in section 402A of the
5 RESTATEMENT (SECOND) OF ToRS § 402A(1) (1965); see Dougherty v. Hooker Chemical
Corp., 540 F.2d 174, 177-78 (3d Cir. 1976); Schrib v. Seidenberg, 80 N.M. 573, 458 P.2d 825,
829 (1969); McGrath v. White Motor Corp., 258 Ore. 583, 484 P.2d 838, 844 (1971).
51 RESTATEMENT (SECOND) OF ToRS § 402A(2) (1965); see Reyes v. Wyeth Labs., 498 F.2d
1264, 1272 (5th Cir.), cert. denied, 419 U.S. 1096 (1974); Reilly v. King County Central Blood
Bank, Inc., 6 Wash. App. 172, 492 P.2d 246, 247 (1971).
52 RESTATEMENT (SECOND) OF TORTS § 402A(2), Comment h at 351 (1965); see Jacobsen
v. Ducommun, Inc., 87 Nev. 240, 484 P.2d 1095 (1971); Incollingo v. Ewing, 444 Pa. 263, 282
A.2d 206, 219 (1971).
' RESTATEMENT (SECOND) OF TorS § 402A(2), Comment j at 353 (1965); see Bryant v.
Hercules Inc., 325 F. Supp. 241, 246 (W.D. Kan. 1970); Incollingo v. Ewing, 444 Pa. 263, 282
A.2d 206, 219 (1971).
Comment k, concerning "unavoidably unsafe products," reiterates this rule by stating
that a properly prepared and marketed drug for which proper warning is given will not give
rise to strict tort liability "merely because [the manufacturer] has undertaken to supply the
public with an apparently useful and desirable product, attended with a known but appar-
ently reasonable risk." RESTATEMENT (SECOND) OF ToRS § 402A(2), Comment k at 354 (1965);
see Reyes v. Wyeth Labs., 498 F.2d 1264, 1275 (5th Cir.), cert. denied, 419 U.S. 1096 (1974);
Fruge v. Blood Services, 365 F. Supp. 1344, 1349 (W.D. La. 1973), aff'd in part, rev'd in part,
506 F.2d 841 (5th Cir. 1975). See also Oresman v. G.D. Searle & Co., 321 F. Supp. 449, 457
(D.R.I. 1971). Directed towards products such as drugs "which, in the present state of human
knowledge" cannot be made completely safe for ordinary use, this comment seeks to balance
the overall public benefit against the injury which may attend the product's use.
RESTATEMENT (SECOND) OF Tors § 402A(2), Comment k at 353 (1965); see Basko v. Sterling
Drugs, Inc., 416 F.2d 417, 425-26 (9th Cir. 1969); Brody v. Overlook Hospital, 127 N.J. Super.
331, 317 A.2d 392, 397 (1974), aff'd, 66 N.J. 448, 332 A.2d 596 (1975); Hines v. St. Joseph's
Hospital, 86 N.M. 763, 527 P.2d 1075, 1106 (1974); Leibowitz v. Ortho Pharmaceutical Corp.,
224 Pa. Super. 418, 307 A.2d 449, 457 (1973).
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Restatement (Second). New York has rejected 402A in its entirety,5
while California has refused to adopt its "unreasonably dangerous"
qualification of "defective." 5 Because the concept of unreasonable
danger forms the heart of the Restatement approach, California's
rejection of that theory would appear to be as complete as New
York's.
The effect of the Restatement's requirement of "proper warn-
ings" of "anticipated dangers" is to place emphasis upon the manu-
facturer's conduct in producing and marketing the drug. As noted
by several commentators, the Restatement apparently carves out an
exception in its strict liability theory, applying standard negligence
principles when the product is a drug."
The Uniform Product Liability Act
Recognizing the inherent differences between construction and
design defects, the proposed Uniform Product Liability Act (the
Draft)57 treats them separately58 and offers no single definition of
"defective." 5 The Draft suggests five factors to be weighed in deter-
mining whether a product's design is defective:
(1) The likelihood at the time of manufacture that the product
would cause the harm suffered by the claimant;
(2) The seriousness of that harm;
(3) The technological feasibility of manufacturing a product de-
signed so as to have prevented claimant's harm;
(4) The relative costs of producing, distributing, and selling such
an alternative design; and
(5) The new or additional harms that may result from such an
alternative design ."
" Micallef v. Miehle Co., 39 N.Y.2d 376, 388, 348 N.E.2d 571, 579, 384 N.Y.S.2d 115,
122 (1976).
" Cronin v. J.B.E. Olson Corp., 8 Cal. 3d 121, 133, 501 P.2d 1153, 1162, 104 Cal. Rptr.
433, 442 (1972).
" See RESTATEMENT (SECOND) OF ToRs § 402A(2), Comment k at 353 (1965); Keeton,
Products Liability-Inadequacy of Information, 48 TEx. L. REv. 398, 408 (1970); Comment,
The Diminishing Role of Negligence in Manufacturers' Liability for Unavoidably Unsafe
Drugs and Cosmetics, 9 ST. MARY's L.J. 102, 105 (1977).
UNIFORM PRODuar IAJumrry Acr (U.P.L.A.), reprinted in 44 Fed. Reg. 2996 (1979).
See U.P.L.A. § 104(A)-(B), reprinted in 44 Fed. Reg. 2998 (1979). The draft recom-
mends that determination of a construction defect should consider both the manufacturer's
specifications and peculiarities of the particular product. More detailed criteria are offered
to determine whether or not a design is defective. Id. See generally Cepeda v. Cumberland
Engineering Co., 76 N.J. 152, W A.2d 816 (1978).
1, See U.P.L.A. § 104, reprinted in 44 Fed. Reg. 2998 (1979).
,0Id.
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These are, in essence, the same factors which the California Su-
preme Court proposed in Barker." Unlike Barker, however, the
Draft places on the plaintiff the burden of proving that the factors
weigh in his favor.2
The analysis accompanying the Draft points out that "no court
yet has imposed true strict or absolute liability on product sellers
for defects in design appreciating, no doubt, the unlimited liability
potential inherent in such cases where it is almost always possible
to design a product more safely." 3 On this premise, the Draft ac-
cepts the notion that a strict liability action for design defects is
impossible and opts instead for a negligence-based standard. For
example, not only is the state of the art as it existed at the time of
manufacture relevant,64 but conformity with the state of the art and
legislative standards raises a rebuttable presumption of nondefec-
tiveness. 5
The Draft is less than innovative in its approach to the design
defect problem. It is, in fact, merely a synopsis of the majority views
in the area of product manufacturer's liability. Although the sources
consulted by the Draft's task force were many and varied,66 the
Draft suffers from a "machine perspective." Applied to machines
and most other products, it provides a sound standard by which the
trier of the fact may determine defectiveness but provides little help
in determining drug defectiveness. In light of present drug testing
practice,6 it is likely that industry custom will be observed and
hazardous aspects, known at the time of manufacture, will be
, See 20 Cal. 3d 413, 573 P.2d 443, 445, 143 Cal. Rptr. 225, 237 (1978); note 39 supra.
'z U.P.L.A. § 104, reprinted in 44 Fed. Reg. 2998 (1979). The Barker court held that once
the plaintiff has shown that the product's design proximately caused the injury, the defen-
dant has the burden of showing that the product was not defective. 20 Cal. 3d at 432-33, 573
P.2d at 455, 143 Cal. Rptr. at 237; see text accompanying notes 42-46 supra.
0 U.P.L.A. § 104(B) (analysis), reprinted in 44 Fed. Reg. 3004-05 (1979).
" U.P.L.A. § 106(b), reprinted in 44 Fed. Reg. 2998 (1979); see Bruce v. Martin-Marietta
Corp., 544 F.2d 442, 447 (10th Cir. 1976).
1 U.P.L.A. § 106(d), reprinted in 44 Fed. Reg. 2999 (1979). The Restatement (Second)
approach, see note 53 supra, is adopted for those products which are "unavoidably unsafe."
U.P.L.A. § 105, reprinted in 44 Fed. Reg. 2998 (1979). See generally Cochran v. Brooke, 243
Or. 89, 409 P.2d 904 (1966); Willig, The Comment k Character: A Conceptual Barrier to Strict
Liability, 29 MERCER L. REv. 545 (1978). If adequate warning is provided, the manufacturer
is absolved from liability for any ensuing injuries. U.P.L.A. § 105(c), reprinted in 44 Fed. Reg.
2998 (1979); see Givens v. Lederle, 556 F.2d 1341, 1345 (5th Cir. 1977); Dalke v. Upjohn Co.,
555 F.2d 245, 247-48 (9th Cir. 1977); Davis v. Wyeth Labs., Inc., 399 F.2d 121, 130 (9th Cir.
1968); Fogo v. Cutter Labs., Inc., 68 Cal. App. 3d 744, 755, 137 Cal. Rptr. 417, 423 (1977).
66 44 Fed. Reg. 2996 (1979). Among the sources used to produce this draft were the
Interagency Task Force on Product Liability, recent cases, and recent law review material.
Id.
67 See note 10 supra.
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either eliminated or adequately warned of. In short, the Draft's
design defect standard offers little guidance in the drug context,
particularly in the area of unforeseeable hazards. While it attempts
to supply a comprehensive scheme for determining manufacturer's
liability, the Draft promises to leave uncompensated a potentially
large number of persons injured by defective drugs.
New York's Pattern Jury Instructions
The authors of New York's Pattern Jury Instructions (PJI) de-
scribe a defective product as one which is "not reasonably safe.""8
The suggested instruction specifically eliminates the need to prove
manufacturer's knowledge of the product's harmful character and
asks instead whether the product is "so likely to be harmful...
that a reasonably prudent person who had actual knowledge of its
harmful character would conclude that it should not have been
marketed in that condition."'" Apparently, then, liability could be
imposed for unforeseen drug injuries under the PJI test because,
although the Restatement's "unreasonably dangerous" definition is
used, it is here joined with time-of-trial hindsight.
The PJI suggests that whether a design is defective depends on
a "balancing of the alternative designs available against the existing
risk while taking into account the cost of the proposed alterna-
tive." 0 These factors fairly approximate those suggested by the Cal-
" NEW YORK PATrERN JURY INSTRUCTIONS (PJI) 2:141 (Supp. 1977).
"Id. (emphasis added).
70 PJI 2:141, comment at 78 (Supp. 1977). In determining whether a product is "not
reasonably safe," the Pattern Jury Instructions (PJI) suggests consideration of the seven
factors proposed by Professor Wade. See Wade, supra note 9. A brief discussion of these
factors will highlight some of the policy considerations inherent in any disposition of the
unforeseeable side effect issue.
(1) "The usefulness and desirability of the product-its utility to the use and to the
public as a whole." Id. at 837. Perhaps another means of expressing this first factor is to
ask-"How valuable is the product?" A lifepreserving drug gains favor under this considera-
tiofi, while one producing a no-essential therapeutic effect suffers a disadvantage when
weighed against attendant risks of injury.
(2) "The safety aspects of the product-the likelihood that it will cause injury and the
probable seriousness of the injury." Id. While a mechanical design can often be scrutinized
for its "safety aspects," a drug's design is hardly amenable to such practical analysis. In light
of the current regulations of the Food and Drug Administration and the practices of the drug
industry, however, the statistical likelihood of serious injury from use of a new drug is rela-
tively low, almost certainly below ten percent. See W. Ross, supra, note 11. Even if it is as
low as one percent or a small fraction thereof, at least one school of thought believes that the
user is entitled to know the risks he is confronting. See generally Gardner, Increasing Patient
Awareness in Drug Therapy: Ramifications of a Patient Package Insert Requirement, 66 GA.
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ifornia Supreme Court in Barker.71 The difference between the two
approaches lies in application rather than substantive content. New
York's PJI asks whether, in light of the relevant factors known at
trial, the product should have been marketed. In California, the
plaintiff need only allege injury due to design and will succeed if
the defendant cannot show that the relevant factors weigh in his
favor. The PJI approach is preferable from the plaintiff's view-
point, notwithstanding that the California standard substantially
reduces the plaintiff's burden of proof. Under both analyses the
essence of the action remains negligence, but the PJI element of
time of trial hindsight greatly erodes the action's negligence char-
acter. 72
Curiously, it appears that no reported New York decision has
commented upon, much less applied, the PJI's knowledge-at-trial
L.J. 837 (1978). From the perspective of a plaintiff who has suffered serious, possibly crippling
harm, "statistical unlikelihood" has a hollow ring.
(3) "The availability of a substitute product which would meet the same need and not
be as unsafe." Wade, &upra note 9, at 837. In the context of drug-related injuries this is a
relatively unimportant factor, because while there are usually a variety of "substitute prod-
ucts" for a particular drug, these substitutes function with varying degrees of effectiveness
and safety.
(4) "The manufacturer's ability to eliminate the unsafe character of the product without
impairing its usefulness or making it too expensive to maintain its utility." Id. Although
redesign of a drug to circumvent, eliminate or minimize side effects might be theoretically
possible, as a practical matter the manufacturer cannot focus his resources in that direction
until the existence of the side effect is known.
(5) "The user's ability to avoid danger by the exercise of care in the use of the product."
Wade, supra, at 837. Careful use presupposes that the consumer knows the potential risks.
This element greatly favors the plaintiff in the context of unforeseeable drug injuries, since
the danger to be avoided is not known at the time of use.
(6) "The user's anticipated awareness of the dangers inherent in the product and their
avoidability, because of general public knowledge of the obvious condition of the product, or
of the existence of suitable warnings or instructions. " Id. Overlapping the concept of user's
knowledge, this factor becomes particularly relevant in the context of warnings and instruc-
tions accompanying a drug product. With unforeseeable side effects, of course, a user's know-
ledge will not result from a specific warning, but only from a generalized realization that all
drugs are potentially dangerous.
(7) "The feasibility, on the part of the manufacturer, of spreading the loss by setting the
price of the product or carrying liability insurance." Id. A 1972 Senate report states that
"[losses, or even low profits, are practically unheard of among large drug companies."
SENATE SUBCOMM. ON MONOPOLY, SELECT COMM. ON SMALL BUSINESS, COMPETITIVE PROBLEMS
IN THE DRUG INDUSTRY, 92d Cong., 2d Sess. 33. (Comm. Print 1972). Coupled with the high
volume of sales in the drug industry, the loss-spreading ability of drug manufacturers is
amply illustrated. Indeed, these profits have been justified by manufacturers on the grounds
of the risk undertaken in new drug development. Id. at 31.
See notes 43-46 supra.
72 See PJI 2:141, comment at 79 (Supp. 1978).
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standard. 3 Other courts, however, have used similar methods of
analysis in determining manufacturer's liability. For example, in
Hamilton v. Hardy,7 the plaintiff suffered a stroke as a side effect
of using the defendant's birth control pill.75 Noting that the evi-
dence required to establish inadequacy of warning is identical
under strict liability and negligence theories,' the Colorado Court
of Appeals succinctly illustrated that the two actions are nonethe-
less dissimilar:
In a strict liability case we are talking about the condition (danger-
ousness) of an article which is sold without any warning, while in
negligence we are-talking about the reasonableness of the manufac-
turer's action in selling the article without a warning. The article
can have a degree of dangerousness because of a lack of warning
which the law of strict liability will not tolerate even though the
actions of the seller were entirely reasonable in selling the article
without a warning considering what he knew or should have known
at the time he sold itY
Implicitly, the Hamilton court determines dangerousness by know-
ledge at trial; otherwise the two principles would be identical.
Some courts, however, have hesitated to impose a knowledge-
at-trial standard upon a manufacturer. In Crocker v. Winthrop
Laboratories, Inc. ,7 for example, the Supreme Court of Texas
stated that, although under certain circumstances "the manufac-
turer should be liable for resulting harm though he did not and
could not have known of the danger at the time of marketing, '79 it
was "not prepared to hold. . . that in the case of a generally bene-
ficial or good product the manufacturer's liability can be predicated
upon . . . those facts known at the time of trial. 8 0 Other courts
have been less ambivalent and absolved the manufacturer simply
on the basis of the defect's unforeseeability. 1
7 See Wade, supra note 9, at 835.
1, 549 P.2d 1099 (Colo. Ct. App. 1976).
15 Id. at 1102.
1, Id. at 1106.
" Id. at 1107.
78 514 S.W.2d 429 (Tex. 1974).
7, Id. at 432.
11 Id. at 433.
8 See, e.g., Bichler v. Willing, 58 App. Div. 2d 331, 397 N.Y.S.2d 57 (1st Dep't 1977);
Friedman v. Medtronic, Inc., 42 App. Div. 2d 185, 345 N.Y.S.2d 637 (2d Dep't 1973); Hoover
v. Franklin Serum Co., 444 S.W.2d 596 (Tex. 1969); Cudmore v. Richardson-Merrell, Inc.,
398 S.W.2d 640, 643 (Tex. Civ. App.), cert. denied, 385 U.S. 1003 (1967).
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POLICY AND ALTERNATIVES
None of the foregoing authorities provides an adequate frame-
work for apportioning losses from injuries caused by unforeseeable
drug defects.82 The New York cases on strict liability for design
defects, focusing as they do on negligence, would effectively shield
the drug manufacturer from all liability. The California cases shift
the burden of proof, but maintain the negligence character of the
strict liability action. Section 402A of the Restatement (Second),
despite its broad language about "unreasonably dangerous"
products, would apply standard negligence principles to drugs. The
draft of the Uniform Product Liability Act lists five factors to be
considered under what is still a negligence test. The only authority
to depart from the standard negligence framework is the New
York PJI, which would evaluate the drug at the time of trial, not
when it was manufactured and marketed, and then apply negli-
gence principles. The PJI would permit the imposition of liability
on manufacturers of defective drugs whose defects could not rea-
sonably have been foreseen.
There are undoubtedly less extreme alternatives which would
neither shield the manufacturer from all liability nor leave the
manufacturer completely exposed to suit. It is unlikely that either
of these extremes represent a proper apportionment of losses from
unforeseen drug defects.13 The proper apportionment ultimately
82 Although a definition of "defect" unique to unknown drug hazards is required before
strict liability can be imposed, the theory of liability remains the same. As the New York
Court of Appeals in Codling noted, the rationale for imposing strict liability applies to those
products "with an alluring exterior. .. [whose] validity and usefulness. .. depend upon
the application of. . . chemical. . . principles far beyond the ken of the average consumer."
32 N.Y.2d 330, 340, 298 N.E.2d 622, 627, 345 N.Y.S.2d 461, 468. Thus, drugs seem particu-
larly susceptible to the strict liability theory and rationale. As Professor Wade has noted,
however, the question of design defectiveness is a theoretical vexation:
[T]he term "defective" raises many difficulties. Its natural application would be
limited to the situation in which something went wrong in the manufacturing
process, so that the article was defective in the sense that the manufacturer had
not intended it to be in that condition. To apply it also to the case in which...
the design turns out to be a bad one or the product is likely to be injurious in its
normal condition, is to use the term in a Pickwickian sense, with a special, esoteric
meaning of its own.
Wade, supra note 9, at 831-32.
" The dilemma posed by these extremes can be approached from the traditional perspec-
tive articulated by Professor James: "[W]hen unexpected dangers develop from the use of
a valuable new product, the industry producing it. . . [should] compensate the innocent
victims of those dangers." James, Products Liability, 34 TEx. L. Rav. 192, 215 (1955). Inter-
estingly, although the Restatement (Second) authors apparently have seen fit to absolve drug
manufacturers where the injury is the result of an unanticipated danger, Comment c to
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must rest on a complex policy determination, best performed by a
legislature, weighing economic, social and political factors. Among
the factors to be considered is the possibility that new product de-
velopment and marketing might be brought to a halt for fear of
potential lawsuits.f A greater potential for liability might prompt
manufacturers to purchase substantially more insurance, the cost of
which might be passed on to consumers in the form of higher prices,
an undesirable result in light of already spiralling medical costs.
Additionally, the cost of adequate liability insurance could make
operation unprofitable for the small manufacturer, while the alter-
native of carrying no insurance at all could destroy a smaller busi-
ness in the event of a costly lawsuit. 5
On the other hand, it might be argued that the threat of per-
sonal injury suits would encourage the development of more precise
and thorough research and testing methods.86 Moreover, it may be
more desirable to spread the loss among all consumers rather than
section 402A adopts the same view as Professor James:
Public policy demands that the burden of accidental injuries caused by products
intended for consumption be placed upon those who market them, and be treated
as a cost of production against which liability insurance can be obtained.
RESTATEMENT (SEcOND) OF TORTS § 402A, Comment c (1965); see Comment, The Diminishing
Role of Negligence in Manufacturer's Liability for Unavoidably Unsafe Drugs and Cosmetics,
9 ST. MARY'S L.J. 102, 115-16 (1977).
Other commentators have analogized drug manufacturers' liability to the earlier tort
concept of ultrahazardous activity, see, e.g., Rheingold, Products Liability-The Ethical
Drug Manufacturer's Liability, 18 RuTGEs L. REV. 947, 1001 & n.308 (1964); Wade, supra
note 9, at 835-36, and conclude that liability for injuries caused by unforeseeable hazards is
the price that manufacturers should pay for engaging in such a business. Rheingold, supra,
at 1001-02, 1017. In the end, it would not be incorrect to say that sufficient authority and
precedent exists for the imposition of strict liability upon the drug manufacturer for injuries
resulting from unforeseeable hazards.
" See Leibowitz v. Ortho Pharmaceutical Corp., 244 Pa. Super. 418, 307 A.2d 449, 458
(Pa. 1973); Connolly, The Liability of a Manufacturer For Unknowable Hazards Inherent in
His Product, 32 INS. COUNSEL J. 303, 306 (1965); Comment, The Diminishing Role of Negli-
gence in Manufacturer's Liability For Unavoidably Unsafe Drugs and Cosmetics, 9 ST.
MARY'S L.J. 102, 112 (1977). Contra, Rheingold, Products Liability-The Ethical Drug Manu-
facturer's Liability, 18 RUTGERS L. REv. 947, 1017 (1964). In connection with this argument,
it has been asserted that society's need for life-preserving drugs demands that the best
production environment possible be made available to drug manufacturers. W. PROSSER, LAW
OF TORTS § 99, at 661-62 (4th ed. 1971).
" As Professor Rheingold has noted, however, "it is hard to imagine any drug company
today whose financial situation is so marginal that it is unable to purchase insurance and
itself be a self-insurer beyond the limits of the coverage." Rheingold, Products Liability-The
Ethical Drug Manufacturer's Liability, 18 RUTGERS L. REV. 947, 1016-17 (1964).
" See Merrill, Compensation for Prescription Drug Injuries, 59 VA. L. REV. 1, 107-09
(1973); Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability, 18
RUTGERS L. REV. 947, 1015 (1964); Comment, The Diminishing Role of Negligence in Manu-
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force the injured party to bear the burden. Indeed, under certain
circumstances the injured party may be the "guinea pig" whose
injury causes the product to be redesigned in the form of revised
warnings or withdrawn from the market to prevent injury to others.
Yet, without making a sweeping policy decision for or against
drug manufacturers' liability, a legislature might make various
minor changes to better apportion losses. Several commentators,
for example, have suggested partial governmental responsibility for
unforeseeable injuries, particularly when the losses are catastrophic
such as in a "Thalidomide"-type disaster. 7 This suggestion is
founded upon the belief that government participation in the mar-
keting of a drug through FDA testing and approval should carry
with it some measure of financial responsibility.8
On the issue of damages, limits or "caps" could be placed on
plaintiffs' recoveries. Several states already have enacted liability-
limiting legislation in the area of medical malpractice. While these
statutes present constitutional questions that are beyond the scope
of this Article,0 it seems clear that this type of limitation could
ameliorate the economic consequences of expanded manufacturers'
liability.
Other more drastic methods include arbitration, 91 elective
no-fault insurance" and governmentally funded social compensa-
facturer's Liability for Unavoidably Unsafe Drugs and Cosmetics, 9 ST. MARY'S L.J. 102, 110
(1977); Comment, Strict Liability in Tort: Its Applicability to Manufacturers of Prescription
Drugs, 7 U. CAL. D.L. REV. 487, 506 (1974). See generally G. CALABRESI, THE COSTS OF
ACCIDENTS 73 (1970).
11 See, e.g., Teff, Products Liability in the Pharmaceutical Industry at Common Law,
20 McGILL L.J. 102, 121 (1974). In the context of governmental responsibility for drug injuries,
it has been stated that "the government should accept at least joint responsibility with a
manufacturer, whose product has met standards of safety set by the government, but from
the use of which any injury or loss has arisen." Id., n.87 (quoting The Pharmaceutical Journal
(1973), Vol 211, No. 5727, 84). See also Rheingold, supra note 80, at 1016.
" Teff, Products Liability in the Pharmaceutical Industry at Common Law, 20 McGML
L.J. 102, 121-22 & n.87 (1974).
11 See, e.g., ILL. REV. STAT. ch. 70 § 101 (Supp. 1978) ($500,000); IND. STAT. ANN. § 16-
9.5-2-2 (Cum. Supp. 1978) ($500,000); Omo REV. CODE ANN. § 2307.43 (Supp. 1978)
($200,000).
1o See Wright v. Central DuPage Hosp. Assoc., 63 Ill. 2d 313, 347 N.E.2d 736 (1976)
(Illinois statute limiting malpractice awards to $500,000 held unconstitutional).
" As one commentator has noted, however, arbitration merely replaces one system with
another, without correcting the problems which are inherent in the typical drug injury case.
See O'Connell, An Alternative to Abandoning Tort Liability: Elective No-Fault Insurance for
Many Kinds of Injuries, 60 MINN. L. REv. 501, 513 (1976).
92 See id.; Freedman, No-Fault and Products Liability: An Answer to a Maiden's Prayer,
1975 INS. L.J. 199; O'Connell, An Alternative to Abandoning Tort Liability: Elective No-
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tion schemes." In contrast to the alternatives already mentioned,
which in varying degrees alter the judicial framework, these pro-
posals constitute entirely new methods of compensation wholly in-
dependent of the judicial system.
The alternatives mentioned are not without their practical im-
perfections. They are suggested merely to demonstrate that un-
foreseeable drug injuries need not go entirely uncompensated and
that compensation for those injuries need not destroy the manu-
facturer. Of course, future legislative possibilities do not help
judges who must charge juries and make decisions today. To do
justice to both injured user and non-negligent manufacturer, the
judge seeks a legal standard which will properly apportion losses
between the parties for injuries resulting from unforeseeable drug
hazards. Unfortunately, the prevailing legal theories of negligence
and strict liability, developed in machinery litigation, are tools too
crude for this delicate job.
Fault Insurance for Many Kinds of Injuries, 60 MINN. L. REv. 501, 513 (1976); O'Connell,
Elective No-Fault by Liability Contract With or Without an Enabling Statute, 1975 U. ILL.
L.F. 59, 72; Schwartz, Professor O'Connell's No-Fault Plan for Products and Services: Have
New Problems Been Substituted for Old?, 70 NEv. U.L. REv. 639 (1975).
11 See Teff, Products Liability in the Pharmaceutical Industry at Common Law, 20
McGILL L.J. 102, 121-22 (1974).
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